Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.

@article{Gandara2010AssociationOE,
  title={Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer.},
  author={David R Gandara and Peter P Grimminger and Philip C. Mack and Paolo Lara and Tianhong Li and Peter V. Danenberg and Kathleen D. Danenberg},
  journal={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2010},
  volume={5 12},
  pages={
          1933-8
        }
}
INTRODUCTION Patients with non-small cell lung cancer (NSCLC) with cancers harboring activating mutations in the epidermal growth factor receptor (EGFR) show improved efficacy from EGFR tyrosine kinase inhibitors. Some clinical studies also suggest enhanced efficacy of platinum-based chemotherapy in patients with EGFR-mutant cancers. We investigated the relationship of EGFR mutation status and DNA repair capacity, as exemplified by excision repair cross-complementing 1 (ERCC1) gene expression… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 33 CITATIONS

Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: implications for therapy.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2013
VIEW 6 EXCERPTS
CITES BACKGROUND

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

  • Archives of Toxicology
  • 2015
VIEW 1 EXCERPT
CITES BACKGROUND
HIGHLY INFLUENCED

Association of EGFR mutations and HMGB1 genetic polymorphisms in lung adenocarcinoma patients

Yi-Liang Wu, Ming-Hsien Chien, +5 authors Shun-Fa Yang
  • Journal of Cancer
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 40 REFERENCES

A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung

JS Lee, K Park, S-W Kim
  • J Thorac Oncol
  • 2009

EGFR mutations detected in plasma are associated with patient outcomes in erlotinib plus docetaxel-treated non-small cell lung cancer.

  • Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2009